Physician profile
Rakesh Gaur
NPI 1780630368
$5,460.87
in general payments reported to CMS, 2019-2025
14 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.85 · 2021: $27.86 · 2022: $281 · 2023: $3,713 · 2024: $350 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,625 · Travel and Lodging: $898 · Grant: $350 · Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,625.00 |
| Travel and Lodging | $898.35 |
| Grant | $350.00 |
| Food and Beverage | $261.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $3,653.71 | 2023 | Kimmtrak |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Alexion Pharmaceuticals, INC. | $600.00 | 2022-2025 | Voydeya, Ultomiris |
| Astrazeneca Pharmaceuticals LP | $350.00 | 2024 | |
| Celgene Corporation | $31.04 | 2022 | |
| Acrotech Biopharma INC. | $27.86 | 2021 | |
| Glaxosmithkline, LLC. | $22.40 | 2023 | Zejula, Jemperli |
| Amgen INC. | $21.40 | 2023 | Blincyto, Kyprolis |
| Exelixis INC. | $20.24 | 2025 | Cabometyx |
| Pfizer INC. | $19.85 | 2025 | |
| Cycle Pharmaceuticals INC | $17.42 | 2025 | Phyrago |
| Astellas Pharma US INC | $16.85 | 2020 | |
| Karyopharm Therapeutics INC. | $15.25 | 2023 | Xpovio |
| Novocure INC. | $14.85 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Gaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.